Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015346 | 0.82 | PRSS1 (0.48) | KMT2AMEN1POLBMAPTBCHE | |
| SCHEMBL24062673 | 0.81 | PRSS1 (0.47) | MAPTBCHEPRSS1TPSAB1ALDH1A1 | |
| SCHEMBL1849023 | 0.81 | MAPT (0.42) | KMT2AMEN1POLBMAPTPKM | |
| SCHEMBL8033783 | 0.80 | ALDH1A1 (0.62) | KMT2AMEN1POLBMAPTPKM | |
| SCHEMBL21896174 | 0.80 | PRSS1 (0.49) | MAPTLMNABCHEPRSS1TPSAB1 | |
| SCHEMBL14415491 | 0.80 | PRSS1 (0.46) | KMT2AMEN1POLBMAPTLMNA | |
| SCHEMBL10107202 | 0.79 | ALDH1A1 (0.56) | KMT2AMAPTLMNABCHEALDH1A1 | |
| SCHEMBL6666839 | 0.79 | LMNA (0.53) | KMT2AMEN1POLBMAPTPKM | |
| SCHEMBL19543351 | 0.78 | LMNA (0.48) | KMT2APOLBMAPTPKMLMNA | |
| SCHEMBL14415495 | 0.77 | PARP10 (0.50) | KMT2AMEN1MAPTBCHEPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | KMT2A 4393/4885MEN1 1679/4885POLB 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.